Eurospital S.P.A.
Italian healthcare company (founded 1948) active in R&D, manufacture and commercialization of pharmaceuticals, medical devices, in‑vitro diagnostics, special nutrition (gluten‑free and low‑protein) and dietary supplements. Maintains internal R&D laboratories for diagnostic assay and molecular kit development, operates clinical and commercial distribution through pharmacy channels in Italy, collaborates with universities and research centers, and publishes periodic sustainability reports while holding multiple quality and regulatory certifications for international markets.
Industries
Nr. of Employees
medium (51-250)
Eurospital S.P.A.
Products
ELISA kits for infectious disease serology
Qualitative and quantitative ELISA kits for detection of antibodies against respiratory viruses, tropical viruses (Chikungunya, Dengue, Zika), hepatitis viruses (HDV, HEV), tick‑borne encephalitis (TBE), TORCH pathogens, and fungal/parasitic agents.
NS1 antigen ELISA for dengue
ELISA assay for detection of Dengue virus NS1 antigen in serum or plasma for early diagnosis of acute infection.
Microfluidic immunofluorescence antigen test and compatible reader
Microfluidics‑based immunofluorescence assay for detection of respiratory virus antigens from nasopharyngeal/oropharyngeal swabs, supplied with a compatible reader instrument for assay processing and signal reading.
Lateral‑flow rapid antigen and antibody tests with reader compatibility
Rapid immunochromatographic tests for antigen and antibody detection from blood or swab samples, offered in formats for self‑testing and professional use and compatible with automated lateral‑flow readers that enable traceability and report generation.
ELISA kits for TORCH and perinatal infection screening
ELISA assays for detection of antibodies to agents in the TORCH complex (Toxoplasma gondii, Rubella, Cytomegalovirus, Herpes simplex) including IgG/IgM and avidity formats for maternal‑fetal risk assessment.
ELISA kits for infectious disease serology
Qualitative and quantitative ELISA kits for detection of antibodies against respiratory viruses, tropical viruses (Chikungunya, Dengue, Zika), hepatitis viruses (HDV, HEV), tick‑borne encephalitis (TBE), TORCH pathogens, and fungal/parasitic agents.
NS1 antigen ELISA for dengue
ELISA assay for detection of Dengue virus NS1 antigen in serum or plasma for early diagnosis of acute infection.
Microfluidic immunofluorescence antigen test and compatible reader
Microfluidics‑based immunofluorescence assay for detection of respiratory virus antigens from nasopharyngeal/oropharyngeal swabs, supplied with a compatible reader instrument for assay processing and signal reading.
Lateral‑flow rapid antigen and antibody tests with reader compatibility
Rapid immunochromatographic tests for antigen and antibody detection from blood or swab samples, offered in formats for self‑testing and professional use and compatible with automated lateral‑flow readers that enable traceability and report generation.
ELISA kits for TORCH and perinatal infection screening
ELISA assays for detection of antibodies to agents in the TORCH complex (Toxoplasma gondii, Rubella, Cytomegalovirus, Herpes simplex) including IgG/IgM and avidity formats for maternal‑fetal risk assessment.
Services
R&D, assay development and production of in‑vitro diagnostic kits across immunoassay, molecular and turbidimetric platforms for clinical laboratories and point‑of‑care settings.
Development and supply of ELISA panels for viral, TORCH, fungal and parasitic serology; antigen detection assays for serum/plasma and swab specimens; and specialized serology tests including avidity assays.
Supply of lateral‑flow rapid antigen and antibody tests, microfluidic immunofluorescence antigen tests and compatible reading instruments that support automated interpretation, sample traceability and reporting.
Formulation, registration and commercial supply of gluten‑free and low‑protein therapeutic foods intended for patients requiring specialized diets; products distributed through pharmacies and specialized retailers.
Collaborative research projects with universities and research centers, on‑demand technical support for laboratories and assistance with regulatory and quality matters related to diagnostics and special nutrition products.
Operational processes and contact channels for reporting and managing adverse reaction reports and safety information, in line with legal requirements and involving external pharmacovigilance service providers where indicated.
R&D, assay development and production of in‑vitro diagnostic kits across immunoassay, molecular and turbidimetric platforms for clinical laboratories and point‑of‑care settings.
Development and supply of ELISA panels for viral, TORCH, fungal and parasitic serology; antigen detection assays for serum/plasma and swab specimens; and specialized serology tests including avidity assays.
Supply of lateral‑flow rapid antigen and antibody tests, microfluidic immunofluorescence antigen tests and compatible reading instruments that support automated interpretation, sample traceability and reporting.
Formulation, registration and commercial supply of gluten‑free and low‑protein therapeutic foods intended for patients requiring specialized diets; products distributed through pharmacies and specialized retailers.
Collaborative research projects with universities and research centers, on‑demand technical support for laboratories and assistance with regulatory and quality matters related to diagnostics and special nutrition products.
Operational processes and contact channels for reporting and managing adverse reaction reports and safety information, in line with legal requirements and involving external pharmacovigilance service providers where indicated.
Expertise Areas
- In‑vitro diagnostics development and commercialization
- Molecular diagnostics and genetic susceptibility testing
- Immunoassay development (ELISA, IFA, line immunoassay, lateral flow)
- Turbidimetric assay development for gastroenterological biomarkers
Key Technologies
- Enzyme‑linked immunosorbent assay (ELISA)
- Indirect immunofluorescence assay (IFA)
- Line immunoassay
- Immunochromatographic lateral‑flow rapid tests
News & Updates
News item about company volunteer activities supporting local associations and community projects.
Announcement of the third sustainability report and related ESG activities, including energy efficiency investments and employee engagement.
Review of commercial strategy and sustainability performance for 2024; summarizes R&D investments and product launches across business areas.
Article on development and outlook for the low‑protein product line and its reception among healthcare professionals and patients.
Announcement of the launch of a line of low‑protein therapeutic foods and formation of the Special Nutrition business area.
First company in its sector in Italy to receive FDA certification for a fecal calprotectin test for inflammatory bowel disease diagnosis.
News item about company volunteer activities supporting local associations and community projects.
Announcement of the third sustainability report and related ESG activities, including energy efficiency investments and employee engagement.
Review of commercial strategy and sustainability performance for 2024; summarizes R&D investments and product launches across business areas.
Article on development and outlook for the low‑protein product line and its reception among healthcare professionals and patients.
Announcement of the launch of a line of low‑protein therapeutic foods and formation of the Special Nutrition business area.
First company in its sector in Italy to receive FDA certification for a fecal calprotectin test for inflammatory bowel disease diagnosis.